Does RIPRETINIB Cause Neoplasm progression? 263 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 263 reports of Neoplasm progression have been filed in association with RIPRETINIB (QINLOCK). This represents 5.9% of all adverse event reports for RIPRETINIB.
263
Reports of Neoplasm progression with RIPRETINIB
5.9%
of all RIPRETINIB reports
20
Deaths
49
Hospitalizations
How Dangerous Is Neoplasm progression From RIPRETINIB?
Of the 263 reports, 20 (7.6%) resulted in death, 49 (18.6%) required hospitalization.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIPRETINIB. However, 263 reports have been filed with the FAERS database.
What Other Side Effects Does RIPRETINIB Cause?
Fatigue (582)
Alopecia (517)
Extra dose administered (357)
Death (356)
Underdose (345)
Nausea (292)
Drug ineffective (291)
Disease progression (290)
Hospitalisation (280)
Constipation (249)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which RIPRETINIB Alternatives Have Lower Neoplasm progression Risk?
RIPRETINIB vs RISANKIZUMAB
RIPRETINIB vs RISANKIZUMAB-RZAA
RIPRETINIB vs RISDIPLAM
RIPRETINIB vs RISEDRONATE
RIPRETINIB vs RISEDRONIC ACID